Novo Shares Slump on Hims’ Wegovy Pill Copycat
Novo Nordisk (NVO) faced a significant share price decline following Hims & Hers Health’s (HIMS) announcement that it wi
Novo Nordisk (NVO) faced a significant share price decline following Hims & Hers Health’s (HIMS) announcement that it will offer a daily oral compounded version of semaglutide, the active ingredient in the blockbuster weight-loss drug Wegovy. This move by HIMS represents a direct assault on Novo’s dominance in the $100 billion obesity market, leveraging U.S. FDA regulations that permit compounding pharmacies to produce copies of drugs currently listed as 'in shortage.' While Novo Nordisk has struggled with supply chain bottlenecks for both Wegovy and Ozempic, third-party telehealth platforms are rapidly filling the void with significantly cheaper alternatives. For investors, this highlights a growing 'patent-around' risk where regulatory loopholes allow competitors to erode market share during supply crunches. While Novo is investing billions in manufacturing capacity (including the pending acquisition of Catalent), the immediate introduction of a convenient pill format by HIMS could pressure Novo’s pricing power and slow its prescription growth. Investors should watch for Novo's upcoming clinical data on its own oral amyretin and semaglutide versions, as well as potential legal or regulatory challenges to the compounding pharmacy exemptions as supply stabilizes.
Watch upcoming earnings, policy statements and sector-level price action for confirmation.
Key Takeaways
- 1Hims & Hers Health announced a daily oral compounded semaglutide, causing Novo Nordisk shares to retreat as investors weigh the impact of low-cost competition.
- 2The move utilizes FDA compounding rules that allow pharmacies to create versions of patented drugs that are in short supply, a status currently held by Wegovy.
- 3HIMS plans to price its weight-loss offerings significantly lower than Novo Nordisk’s $1,350-per-month list price, targeting the out-of-pocket consumer market.
- 4Novo Nordisk is currently expanding its manufacturing footprint via the $16.5 billion Catalent deal to resolve the very shortages that enable these 'copycat' competitors.
- 5This development follows similar moves by Eli Lilly (LLY) competitors, signaling a broader trend of telehealth platforms commoditizing the GLP-1 sector.
Novo Nordisk (NVO) faced a significant share price decline following Hims & Hers Health’s (HIMS) announcement that it will offer a daily oral compounded version of semaglutide, the active ingredient in the blockbuster weight-loss drug Wegovy. This move by HIMS represents a direct assault on Novo’s dominance in the $100 billion obesity market, leveraging U.S. FDA regulations that permit compounding pharmacies to produce copies of drugs currently listed as 'in shortage.' While Novo Nordisk has struggled with supply chain bottlenecks for both Wegovy and Ozempic, third-party telehealth platforms are rapidly filling the void with significantly cheaper alternatives. For investors, this highlights a growing 'patent-around' risk where regulatory loopholes allow competitors to erode market share during supply crunches. While Novo is investing billions in manufacturing capacity (including the pending acquisition of Catalent), the immediate introduction of a convenient pill format by HIMS could pressure Novo’s pricing power and slow its prescription growth. Investors should watch for Novo's upcoming clinical data on its own oral amyretin and semaglutide versions, as well as potential legal or regulatory challenges to the compounding pharmacy exemptions as supply stabilizes.